Identifying the Intergenic ALK Fusion LOC388942-ALK as a Driver of Non–Small Cell Lung Cancer

Abstract

ALK fusions, such as the classic EML4-ALK, are known drivers of lung cancer and effective therapeutic targets. However, variant ALK fusions, including intergenic fusions like LOC388942-ALK (LA), have been detected in increasing numbers of patients, with their roles in tumorigenesis and ALK inhibitor resistance remaining unclear. Using CRISPR/Cas9, we generated the LA fusion in A549 and H441 cells, confirming elevated ALK expression via qRT-PCR and immunohistochemistry (IHC) staining. Functional analyses showed that LA significantly promoted tumor growth in vitro and in vivo while conferring increased resistance to alectinib. RNA-seq revealed upregulation of the FOS pathway in LA tumors, identifying FOS as a potential therapeutic target. Subsequently, we demonstrated that FOS disruption and inhibition sensitized LA tumors to treatment. RNA-seq profiling demonstrated that FOS depletion in LOC388942-ALK tumor significantly downregulated multiple oncogenic pathways related to cell cycle progression, DNA replication fidelity, and extracellular matrix remodeling, suggesting a pivotal role of FOS in maintaining tumor growth. These findings establish LOC388942-ALK as a novel oncogenic driver in lung cancer, highlighting its role in tumor growth and ALK inhibitor resistance. Targeting FOS may provide a promising therapeutic strategy for tumors harboring this intergenic fusion.

Keywords

ALK fusion / FOS / intergenic fusion / non–small cell lung cancer / tumorigenesis

References

[1] P. Chen, Y. Liu, Y. Wen, and C. Zhou, “Non-Small Cell Lung Cancer in China,” Cancer Communication 42 (2022): 937-970.

[2] G. Harada, S. R. Yang, E. Cocco, and A. Drilon, “Rare Molecular Subtypes of Lung Cancer,” Nature Reviews Clinical Oncology 20 (2023): 229-249.

[3] S. S. Zhang, M. Nagasaka, V. W. Zhu, and S. I. Ou, “Going Beneath the Tip of the Iceberg. Identifying and Understanding EML4-ALK Variants and TP53 Mutations to Optimize Treatment of ALK Fusion Positive (ALK+) NSCLC,” Lung Cancer 158 (2021): 126-136.

[4] E. N. Imyanitov, A. G. Iyevleva, and E. V. Levchenko, “Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives,” Critical Reviews in Oncology/Hematology 157 (2021): 103194.

[5] Y. Chu, M. Chen, and Y. Wei, et al., “Targeting the ALK-CDK9-Tyr19 Kinase Cascade Sensitizes Ovarian and Breast Tumors to PARP Inhibition via Destabilization of the P-TEFb Complex,” Nature Cancer 3 (2022): 1211-1227.

[6] Z. Wen and D. Xiong, S. Zhang, et al., “Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient with Gastric Cancer,” Frontiers in Oncology 11, (2021): 645370.

[7] J. L. Schneider, J. J. Lin, and A. T. Shaw, “ALK-Positive Lung Cancer: A Moving Target,” Nature Cancer 4 (2023): 330-343.

[8] T. Mok, D. Camidge, and S. Gadgeel, et al., “Updated Overall Survival and Final Progression-Free Survival Data for Patients With Treatment-Naive Advanced ALK-Positive Non-Small-Cell Lung Cancer in the ALEX Study,” Annals of Oncology 31 (2020): 1056-1064.

[9] A. T. Shaw, T. M. Bauer, F. de Marinis, et al., “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer,” New England Journal of Medicine 383 (2020): 2018-2029.

[10] S. I. Ou, V. W. Zhu, and M. Nagasaka, “Catalog of 5' Fusion Partners in ALK-Positive NSCLC Circa 2020,” JTO Clinical and Research Reports 1 (2020): 100015.

[11] J. Zhang, C. Zou, C. Zhou, et al., “A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib,” Journal of Thoracic Oncology 15 (2020): 1073-1077.

[12] A. F. Palazzo and E. S. Lee, “Non-Coding RNA: What Is Functional and What Is Junk?” Frontiers in Genetics 6(2015): 2.

[13] J. W. Yun, L. Yang, H. Park, et al., “Dysregulation of Cancer Genes by Recurrent Intergenic Fusions,” Genome Biology 21 (2020): 166.

[14] Y. Dai, P. Liu, W. He, et al., “Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions,” Frontiers in Oncology 12 (2022): 813158.

[15] X. Zhai, Y. Liu, Z. Liang, et al., “Classical ALK G1202R Resistance Mutation Was Identified in a Lung Adenocarcinoma Patient With Rare LOC388942-ALK Fusion After Sequential Treatment With ALK-TKIs and Anlotinib: A Case Report,” Annals of Translational Medicine 10 (2022): 1180.

[16] S. Liao, H. Sun, J. Wu, et al., “Case Report: Two Novel Intergenic Region-ALK Fusions in Non-Small-Cell Lung Cancer Resistant to Alectinib: A Report of Two Cases,” Frontiers in Oncology 12 (2022): 916315.

[17] Z. Q. Wang, J. Liang, K. Schellander, E. F. Wagner, and A. E. Grigoriadis, “c-fos-Induced Osteosarcoma Formation in Transgenic Mice: Cooperativity With c-jun and the Role of Endogenous c-fos,” Cancer Research 55 (1995): 6244-6251.

[18] K. Lu, H. Wang, Y. Tu, et al., “Suppressing c-FOS Expression by G-Quadruplex Ligands Inhibits Osimertinib-Resistant Non-Small Cell Lung Cancer,” Journal of the National Cancer Institute 115 (2023): 1383-1391.

[19] T. Beardslee and J. Lawson, “Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer,” Journal of the Advanced Practitioner in Oncology 9 (2018): 94-101.

[20] K. D. Davies, A. T. Le, J. Sheren, et al., “Comparison of Molecular Testing Modalities for Detection of ROS₁ Rearrangements in a Cohort of Positive Patient Samples,” Journal of Thoracic Oncology 13 (2018): 1474-1482.

[21] W. Li, Y. Liu, W. Li, L. Chen, and J. Ying, “Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC,” Journal of Thoracic Oncology 15 (2020): 1223-1231.

[22] J. L. Schneider, J. J. Lin, and A. T. Shaw, “ALK-Positive Lung Cancer: A Moving Target,” Nature Cancer 4 (2023): 330-343.

[23] Z. Shi, K. Pang, Z. Wu, et al., “Tumor Cell Plasticity in Targeted Therapy-Induced Resistance: Mechanisms and New Strategies,” Signal Transduction and Targeted Therapy 8 (2023): 113.

[24] S. Liu, J. Zhang, L. Yin, et al., “The lncRNA RUNX1-IT1 Regulates C-FOS Transcription by Interacting With RUNX1 in the Process of Pancreatic Cancer Proliferation, Migration and Invasion,” Cell Death & Disease 11 (2020): 412.

[25] X. Qu, X. Yan, C. Kong, et al., “c-Myb Promotes Growth and Metastasis of Colorectal Cancer Through c-fos-Induced Epithelial-Mesenchymal Transition,” Cancer Science 110 (2019): 3183-3196.

[26] M. Riedel, M. F. Berthelsen, H. Cai, et al., “In Vivo CRISPR Inactivation of Fos Promotes Prostate Cancer Progression by Altering the Associated AP-1 Subunit Jun,” Oncogene 40 (2021): 2437-2447.

[27] J. M. González, A. Navarro-Puche, B. Casar, P. Crespo, V. Andrés, “Fast Regulation of AP-1 Activity Through Interaction of Lamin A/C, ERK1/2, and c-Fos at the Nuclear Envelope,” Journal of Cell Biology 183 (2008): 653-666.

[28] Y. Wang, S. Shen, P. Hu, D. Geng, R. Zheng, and X. Li, “Alectinib Versus Crizotinib in ALK-Positive Advanced Non-Small Cell Lung Cancer and Comparison of Next-Generation TKIs After Crizotinib Failure: Real-World Evidence,” Cancer Medicine 11 (2022): 4491-4500.

[29] Y. Zhang, L. Zeng, C. Zhou, et al., “Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC,” Journal of Thoracic Oncology 15 (2020): 1027-1036.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.